| Authors: |
Shigeta K; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Urology, Keio University School of Medicine, Tokyo, Japan., Takamori S; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ozawa H; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Haratake N; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Onishi M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Daimon T; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Urology, Keio University School of Medicine, Tokyo, Japan., Kitano T; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bhattacharya A; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Fushimi A; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Oya M; Department of Urology, Keio University School of Medicine, Tokyo, Japan., Long MD; Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Kufe D; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Donald_Kufe@dfci.harvard.edu. |
